NEW YORK, May 23 – Promega marked its entry into the genotyping market Wednesday, announcing that it would make its ReadIt system commercially available to select laboratories.
“We are now launching a controlled sales program where we carefully identify our prospect and offer a lot of support and help,” said Richard Schifreen, business unit leader for Promega’s molecular diagnostics business.
Schifreen said that one of ReadIt’s main advantages over other SNP-scoring products currently on the market, is that ReadIt allows users to design their own assays.
“A homebrew lab can take the ReadIt system to develop their own assays,” Schifreen said. “We provide them with software tools and support and they buy their oligo probes from anybody.”
ReadIt customers receive enzyme and PCR purification reagents from Promega, a CD-Rom calculator that transfers, analyzes, and scores the data, and access to the company’s probe-design software. The customer has the flexibility to decide what particle handling and liquid dispensing instrumentation and luminometer they would like to use.
Schifreen said ReadIt was designed for low- to medium-throughput and “competitively” priced at about $2.50 - $3.50 per assay. He added that Promega does not retain any reach-through costs for any diagnostic tools that might be developed using ReadIt.
While Promega of Madison, Wis., is not currently designing its own assays, Schifreen said that the company was thinking about developing that business in the future.
The Medical College of Wisconsin is one of the first customers of the ReadIt system.